Memo
To:
Marvin Koslow
From:
Lin, Ken
Date:
2025/5/25
Re:
Datril Action Plan
Word count: 1,000 max
Executive Summary
The single most rewarding opportunity faced by the company is to regain profitable growth in the
fast-expanding acetaminophen segment . This situation is an opportunity because this move can
deliver ≥ 25 % share within nine months and > $10 MM operating profit in Year 1 while
protecting our overall analgesic franchise (see Exhibit 2). To take advantage of this opportunity
the company should launch Datril with a time-bound introductory price, immediate functional
upgrade, and channel-lock defence.
Situation Overview
The single most rewarding opportunity faced by the company is using a $1.00 “price umbrella”
separates consumer willingness-to-pay from Tylenol’s current shelf price.
This situation is an opportunity because with category volume growing 5× faster than aspirin,
entering now with a structured three-step play—penetrate, differentiate, defend—offers the
highest performance upside (Exhibit 1).
Action Overview
To take advantage of this opportunity the company should implement the following action plan.
Strategy:

Target. Our target customers are conscious adults seeking stomach-friendly pain relief
currently using Tylenol or aspirin.

Competitors. We compete with Tylenol (Primary) and private-label acetaminophen and
legacy aspirin brands (Secondary).

Value proposition. Our value proposition is “Fast-acting, pharmacy-trusted acetaminophen
that costs less today and works faster tomorrow—backed by Bristol-Myers science.“
Tactics:

Product. Launch Datril Fast-Relief Caplet—rapid-dissolve coating, tamper-evident seal;
100-count bottle.

Service. 24-h helpline, pharmacist tool-kits explaining bioequivalence and fast-relief
benefit.

Brand. Distinct red Datril logo plus “A Bristol-Myers Product” quality seal; safety imagery
foregrounded.

Price. Intro MSRP $1.99 (6-month “launch price”), then graduate to $2.19-$2.39 keeping a
5–10 % edge on Tylenol.

Incentives. Retail: $0.70 first-case, 10 % off-invoice for 90 days, display allowance.
Consumer: $0.25 FSI & on-pack coupon after promo period ends.

Communication. Split-screen TV/print: “Same acetaminophen—acts faster—save today.”
Shift focus to speed & safety after month 6.

Distribution. Leverage Bufferin/Excedrin network; secure 90 % ACV in drug & grocery
within 4 months; sign 3-facing captain agreements with top chains.
Action Rationale
The proposed action is the best approach to take advantage of the identified opportunity for the
following reasons:

Step 1: Penetrate via limited-time price—drives rapid trial without locking us into a
margin-killing MSRP; creates urgency for retailers to stock up.

Step 2: Differentiate on function & safety—fast-relief coating and superior packaging shift
competition away from easily copied price.

Step 3: Defend with channel and portfolio synergies—display contracts, coupon tactics, and
umbrella management with Excedrin/Bufferin stabilise long-term margins.

Risk mitigation. If Tylenol price-matches, we pivot creative to fast-relief benefit; if
advertising war escalates, pre-approved budget keeps Share-of-Voice ≥70 % of leader;
cannibalisation limited by carving Datril as economy/fast tier while Bufferin and Excedrin
hold premium niches.
Conclusion
The above analysis reflects our strong belief that the proposed course of action reflects the best
approach to take advantage of the identified opportunity to ensure the company’s long-term
success.
Exhibits
The above analysis is supported by the attached exhibit(s) as follows:
Exhibit 1: Three-Step Launch Timeline & Share Milestones
Objective: reach ≥25 % share of the U.S. acetaminophen market within 9 months and sustain
≥30 % within three years.
Phase
Months
Key Action
Planned
MSRP
Projected Share
Step 1 Launch
0-6
Introductory price,
$15 MM media burst,
trade buy-in
$1.99
25 %
Step 2 Differentiate
6-18
Fast-Relief Caplet +
safety packaging + brand
platform
$2.19
28 %
Step 3 Defend &
Grow
18-36
Line extensions, coupon
tactics, combo shelf
strategy
$2.39
30 %
Exhibit 2: Financial Forecast (Year 1 vs Year 3)
Assumptions
Year 1
Year 3
Average MSRP
$1.99
$2.39
Average wholesale price
$1.15
$1.40
Volume (bottles)
35 MM
45 MM
COGS per bottle
$0.60
$0.60
Media & promotion
$15
$18
Trade/consumer discounts
$2
$3
Year 1
Year 3
Net sales
40.2
63.0
COGS
21.0
27.0
Gross profit
19.2
36.0
Operating profit
2.2
15.0
P&L Summary
Result: Operating profit grows from $2.2 MM in Year 1 to $15.0 MM in Year 3 as price and
volume lift.